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Cardiovascular Topics
Summary
The mechanisms causing different supraventricular 
tachycardias can be identified with the aid of the 12-lead 
ECG using Tipple’s approach. The main aims of this 
retrospective study were to use the 12-lead ECG to 
determine the underlying mechanisms of supraventricu-
lar arrhythmias and to evaluate the effectiveness of the 
treatment modalities used.
Forty-one patients were included in the study. The 
main findings were: nine of the 41 patients had atrial 
tachycardias while junctional tachycardia occurred in 
32/41 of our patients. The underlying mechanisms caus-
ing the junctional tachycardias were: AVNRT (n = 21), 
AVRT (n = 10) and JET (n = 1). Of the 10 patients 
presenting with AVRT, eight were less than one year old. 
AVNRT occurred more often in the older age group (>1 
year of age). Fifteen of the 41 patients had spontaneous 
cessation of their supraventricular tachycardia.
The drug most commonly used during the acute and 
long-term phases was digoxin. Amiodarone was used in 
six patients with an 80% success rate. In the early 80s 
verapamil was used in five patients with a 100% success 
rate. It is important to note that verapamil is no longer 
used in children due to its side effects. Lately, adenosine 
phosphate is the drug of choice in most supraventricular 
tachycardias. 
The management of supraventricular tachycardias in 
paediatric practice is mainly based on clinical studies 
and individual experience. Care must therefore be taken 
to choose medication regimens that are likely to be effec-
tive with the minimum risk of potentiating abnormal 
haemodynamics or conduction.
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Supraventricular tachycardia, previously known as parox-
ysmal atrial tachycardia, is the most common significant 
arrhythmia in children.1,2 The incidence of supraventricular 
tachycardia is estimated to be one in 250 to 1 000 children, 
which is far higher than the previously quoted (1967) 
incidence of one in every 25 000 children.3 As methods 
of detection of arrhythmia improved, awareness of this 
condition increased. During the same time period, the 
number of cardiac surgery survivors have increased and so 
also the incidence of supraventricular tachycardia, which is 
one of the more common late postoperative complications.1
Information obtained by electrophysiological studies and 
ablation procedures furthered our understanding of the 
mechanisms causing supraventricular tachycardia, so that 
now, with the aid of the standard 12-lead electrocardiogram 
(ECG), most mechanisms causing arrhythmias can be 
diagnosed without invasive procedures.4
Three main mechanisms causing supraventricular tachy-
cardias were identified: re-entry, abnormal automaticity and 
triggered activity.2 It is generally agreed that accessory 
AV connections in certain types of supraventricular tachy-
cardia are developmental anomalies.5 Therefore, in children 
younger than 12 years of age, supraventricular tachycardias 
are usually caused by an accessory atrioventricular con-
nection.5 In the teenage years, atrioventricular nodal re-
entrant tachycardia (AVNRT) is the commonest cause of 
supraventricular tachycardia.2 
No data could be found of a South African study 
regarding supraventricular tachycardias in children.
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Aim
The aims of this study were to analyse the demographic data 
of patients presenting with supraventricular tachycardias, 
to use the 12-lead ECG to determine the underlying 
mechanisms of the arrhythmia and to evaluate the effective-
ness of the treatment modalities used.
Materials and methods
Supraventricular tachycardia is a rapid heart rate resulting 
from an abnormal mechanism, which originates proximal 
to the bifurcation of the bundle of His.1 The rate of the 
tachycardias ranges from 220 to 320 beats per minute in 
infants, and from 150 to 250 beats per minute in older 
children.2
Based on the characteristics of the tachycardia, patients 
were divided into two groups: primary atrial tachycardias 
and atrioventricular (AV) junctional tachycardias. The 
12-lead ECG recording was used to identify the underlying 
causative mechanism of the supraventricular tachycardia, 
making use of an algorithm, as suggested by MA Tipple.6
Electrocardiographic diagnosis of 
supraventricular arrhyth mias (MA Tipple)6
(a) Identify P wave:
Present:
Upright in II,  Sinus rhythm, sinus node, sinoatrial re-
III, AVF: entry, high ectopic focus.
Negative in II, Atrioventricular re-entry (AVRT), low
III, AVF: ectopic focus.
Absent:
Sinus node Atrioventricular nodal re-entry tachycar-
disease: dia (AVNRT), ectopic tachycardia (JET)
(b) P wave morphology:
Normal:  Sinus tachycardia, sinus node re-entry, 
sinoatrial re-entry.
Abnormal:  Ectopic atrial tachycardia, atrial flutter, 
atrial fibrillation.
(c) Relationship of P to QRS:
Proceeding:  Sinus tachycardia, atrial tachycardia, 
long PR re-entrant tachycardia.
After: AVNRT, AVRT.
(d) Presence of AV or VA block:
Atrial rate > Sinus tachycardia, atrial tachycardia.
ventricular rate:
Ventricular rate > JET.
atrial rate:
All surface ECG tracings were taken at the usual paper 
speed (25 mm/sec) with usual standardisation (1 mV/10 
mm). We infer the presence of a P-wave if the T-wave is 
quite pointed or if a notch is visible on the T-wave.
Definitions
Primary atrial tachycardia is that in which the primary 
electrophysiological disturbance is restricted to atrial tissue 
and it includes: sinus tachycardia, sinus node re-entry, ectopic 
atrial tachycardia, atrial fibrillation, atrial re-entrant tachy-
cardia and atrial flutter.6 Atrially driven tachycardias have 
identifiable atrial activity preceding each QRS complex.
Atrioventricular tachycardias require the atrioventricular 
(AV) junction as a necessary component and include 
AV re-entrant tachycardia using an accessory connection, 
atrioventricular node re-entrant tachycardia (AVNRT) and 
junctional ectopic tachycardia (JET).6 These tachycardias 
usually have an abnormal P-wave morphology and axis, 
which indicate a focus other than the sinus node.
Reciprocating tachycardias involve accessory pathways:
• Orthodromic reciprocating tachycardia is the most com-
mon form where activation is from atria to ventricles 
through the normal AV node, returning via the accessory 
pathway to the atria.5 A narrow QRS complex results, 
during which P-waves are inscribed after the QRS 
complex (RP > PR).
• Antidromic reciprocating tachycardia shows a prolonged 
QRS duration with conduction anterograde over an 
access ory connection and retrograde conduction via 
either the AV node or an additional accessory connec-
tion.7
• In Wolff-Parkinson-White, an accessory pathway (e.g. 
Bundle of Kent) links the atria and ventricles and 
bypasses the AV node. The pathway might manifest itself 
by a delta wave in sinus rhythm or might be concealed 
when it operates only during the tachycardia.4
Atrioventricular nodal re-entry tachycardia (AVNRT) is 
due to re-entry within the AV node and is caused by a circuit 
operating within and in the proximity of the AV node. 
Although AV node anatomy and function are incompletely 
understood, patients with dual AV nodal physiology may 
be considered to have functional slow and fast AV nodal 
pathways. The usual tachycardia of AVNRT is based on an 
anterograde propagation of the impulse through the slow 
pathway and by faster and retrograde activation through 
the fast pathway.5
Junctional ectopic tachycardia (JET) usually occurs in 
the very young, or postoperatively and is characterised by 
an abnormal P-wave axis, normal QRS axis and significant 
variability in overall rate.
Design
This is a retrospective, descriptive study of 41 children 
admitted from 1982 to 1998 with supraventricular tachy-
cardias. The following data were extracted from the patient 
folders:
• Age at onset of the first episode of supraventricular 
tachycardia
• Gender
• Predisposing factors such as: fever, sepsis, drugs, thyroid 
abnormalities, myocarditis
• Associated factors such as: congenital heart disease, 
postoperative to cardiac surgery and Wolff-Parkinson-
White (WPW) syndrome
• Signs and symptoms present with initial episode
• Presence of congestive heart failure with the first episode
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• Type and response of initial treatment for the first 
episode (success is defined as a cessation of supraven-
tricular tachycardia for at least one hour)
• Long-term treatment and response to such treatment
• Presence of supraventricular tachycardia on follow-up (at 
least one episode of ECG-documented supraventricular 
tachycardia within one year of the last clinic visit).
Inclusion criteria
Children younger than 13 years of age had to have had a 
12-lead surface ECG, or 24-hour ambulatory Holter study, 
taken during the supraventricular tachycardia and in sinus 
rhythm.
Exclusion criteria
Incomplete data or absence of a 12-lead surface ECG or 
24-hour Holter study.
Results 
There were 41 patients who fulfilled the inclusion criteria: 
22 males and 19 females (ratio M:F = 1,18:1) with a mean 
age of 3 months (range: in utero to 13 years) at presentation. 
Twenty of the patients, 13 male and 11 female, were less 
than 1 year of age. The age of onset and the gender of the 
patients are displayed in Fig 1. 
Predisposing and associated factors were found in 
49% of patients and are summarised in Table I. The 
most common complaint in older patients (>1 year of age) 
was of palpitations. Fifteen of the 16 patients presenting 
with congestive heart failure were less than one year of 
age.
Junctional tachycardia occurred in 32/41 of our patients, 
while atrial tachycardia was present in 9/41. The underly-
ing mechanisms causing the junctional tachycardias were: 
AVNRT (n = 21), AVRT (n = 10) and JET (n = 1). Of the 
10 patients presenting with AVRT, eight patients were less 
than one year of age. AVNRT occurred more often in the 
older age group (>1 year of age).
Fifteen of the 41 patients presenting with supraventricu-
lar tachycardia had spontaneous cessation of their supraven-
tricular tachycardia (atrial tachycardia two patients, AVNRT 
nine and AVRT four). The response to treatment of the 
remaining 26 patients is summarised in Table II.
Digoxin was the drug most commonly used and was 
successful in terminating the supraventricular tachycardia in 
81% of patients. Synchronised DC electrical cardioversion 
was the next most common method used, with a success 
rate of 43%. Verapamil (five patients) as well as amiodarone 
TABLE I. PREDISPOSING AND OTHER FACTORS ASSOCIATED WITH SUPRAVENTRICULAR TACHYCARDIA
 Associated factors  Predisposing factors
Age (months) Pre-op CHD  Postop CHD WPW Myocarditis Fever Sepsis Drugs
Foetal VSD, PDA      Mother, lofepramine
0.25 Ebstein      
0.5 VSD, PDA      
0.5   *   * 
0.5   * *   
0.5   *    
0.7   *  *  
1     *  
1   *    
1    *   
1.5 PDA      
2   * *   
2   *    
3 Floppy mitral valve     E. coli 
3     *  
5.5    *   
8     *  
16  VSD     
84   *    
144   *    
Total 5 1 9 4 4 2 1
Abbreviations: CHD = congenital heart disease; WPW = Wolff-Parkinson-White syndrome; VSD = ventricular septal defect; PDA 
= patent ductus arteriosus; Pre-op = pre-operative; Postop = postoperative.
Fig. 1. Age at onset of supraventricular tachycardia 
and gender
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(six patients) had a success rate of 100% and 80% respec-
tively, with no complications or fatalities. Vagal stimulation 
(carotid sinus massage) was successful in only one seven-
year-old patient. In the three infants where vagal stimulation 
was tried it was ineffective. 
After the initial cardioversion, 80% of patients were put 
on long-term treatment. Digoxin was used in 77% of these 
patients. Twelve of the 33 patients on long-term therapy had 
breakthrough episodes within the first year after initiation 
of therapy for supraventricular tachycardia. Two patients 
received radio-frequency ablation. After adjustment of the 
dosage of the drugs, none of the remaining 10 patients had 
any breakthroughs. 
Thyroid function tests were done every six months in 
patients on amiodarone. One developed hypothyroidism 
and one a retinopathy. Both these abnormalities normalised 
after discontinuation of the drugs.
All patients younger than one year of age were kept on 
maintenance therapy for two years after the last documented 
episode of supraventricular tachycardia before discontinua-
tion of therapy.
Discussion
Supraventricular tachycardia is a common abnormality of 
heart rhythm in the paediatric patient, often presenting 
before the age of four months.1,8 Thirty per cent of infants 
lose supraventricular tachycardia inducibility by one year of 
age and therefore clinical supraventricular tachycardia recur-
rences are uncommon. Some children have no recurrences of 
supraventricular tachycardia after the initial presentation.9
The term supraventricular tachycardia includes a wide 
variety of causative mechanisms, which were brought to the 
fore by electrophysiologic studies. These mechanisms are 
re-entry tachycardias, increased automaticity and increased 
triggered activity. Some of these mechanisms are confined 
to the atria while others involve both atria and ventricles. 
Classifying the tachycardia by its mechanism and origin, 
as well as determining associated risk factors for treatment 
(such as congenital heart disease, myocarditis, cardiomy-
opathy) allow the clinician to choose the best treatment 
modality for the patient. It is therefore no longer adequate 
to identify a narrow-complex tachycardia as a paroxysmal 
supraventricular tachycardia.7,14
Studies have shown that the clinical features, predispos-
ing and associated factors, mechanisms of supraventricular 
tachycardia, subsequent responses to treatment and the 
eventual outcome of patients presenting with supraventricu-
lar tachycardia vary greatly according to the patient’s age. 
The data in our study correlate with these findings.
Fifty-four per cent of children in our study had their first 
episode of supraventricular tachycardia before four months 
of age. These findings correlate with Garson et al.1 and 
Anderson et al.,10 who reported incidences of 38% and 59% 
respectively. There were 13 male and 11 female infants 
under the age of one year. The male preponderance of 
supraventricular tachycardia when the onset is in infancy 
has been verified in several reports, but is not found in any 
age groups after infancy.11
Predisposing or associated factors were present in 49% 
of the patients and included myocarditis, fever, infection 
and drug exposure (24%), WPW syndrome (22%), and 
congenital heart disease (15%). Ninety-four per cent of 
 TABLE II. EMERGENCY TREATMENT OF SUPRAVENTRICULAR TACHYCARDIA AND RESPONSE
   Age Heart  Vagal DC 
   (months) failure manoeuvres cardioversion Adenosine Digoxin Verapamil Amiodarone
 Primary  0 No    Yes  
 atrial   0 No  No  No  Yes
 tachycardia  0.25 Yes  No    Yes
   0.5 Yes   Yes   
   1.5 Yes    Yes  
   2 Yes    Yes  
   3 Yes    Yes Yes 
 Junctional AVNRT 0 Yes  Yes Yes   Yes
tachycardia  0.3 No    Yes   
   0.5 Yes  No  No  Yes 
   1 Yes  Yes  No  No 
   1 Yes    Yes   
   1 Yes     Yes  
   1 No    Yes Yes  
   3 Yes No   Yes   
   8 No No   Yes   
   72 No   Yes    
   84 No    Yes   
   96 No     Yes
  AVRT 0 No    Yes   
   0.5 Yes  Yes No    
   0.7 Yes    Yes   
   2 Yes  No   Yes  
   2 Yes No   Yes   
   84 No Yes
  JET 16 Yes      Yes
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patients with congestive heart failure occurred in patients 
under the age of one year.
Intravenous digoxin was the most frequently used drug 
and had a success rate of 81%. The mothers of three babies 
with foetal tachycardia received digoxin during pregnancy. 
It was successful in two of the three cases. Newer studies 
also suggest the use of sotalol for antenatal supraventricular 
tachycardias because it passes freely through the placental 
barrier.12
Cardioversion has been reported as being 98% success-
ful in the acute treatment of supraventricular tachycardia.13 
Synchronised direct electrical current cardioversion had a 
success rate of 43% in our study. This might be due to 
an insufficient energy dose delivered. The maximum dose 
that was given to the four patients that did not respond 
was 2 watt-sec/kg, which is far less than the recommended 
maximum dose of 10 watt-sec/kg.6
Verapamil, which was used during the early 1980s, was 
 TABLE III. GUIDELINES FOR THE TREATMENT OF SUPRAVENTRICULAR TACHYCARDIAS
 Type of
 supraventricular
 tachycardia  Termination  Maintenance treatment
 Drugs/other options  Dose Drug Dose (oral/day) Doses/day
Sinus tachycardia Treat underlying cause    
 
Atrial tachycardia:
ectopic and multi- Amiodarone 5 mg/kg ivi loading Amiodarone  2–5 mg/kg 1
focal tachycardia Digoxin  30 mcg/kg Digoxin 10 mcg/kg 2
Sinoatrial re-entrant See AVNRT/AVRT 
Atrial fibrillation 1. Haemodynamically unstable:
and flutter DC cardioversion (1) 0.25–2 J/kg d,l-sotalol (5) 2–8 mg/kg 2
  2. Haemodynamically stable:  Amiodarone 2–5 mg/kg 1
  a) No CHF: (2)
  Amiodarone 5 mg/kg ivi loading WPW: 1–3 mg/kg 3–4
    Propanolol (7)
  b) No CHF:
  Procainamide infants 5–7mg/kg
   children 7–15 mg/kg
   slow ivi
  Ibutilide 0.01 mg/kg ivi
AVNRT and AVRT 1. Haemodynamically unstable:  Digoxin 10 mcg/kg 2
  DC cardioversion (1) 0.25–2 J/kg
  Oesophageal overdrive  pacing  Propanolol 1–3 mg/kg 3–4
  2. Haemodynamically  stable:  d,l-sotalol 2–8 mg/kg 2
  Vagal manoeuvres (3)
  Adenosine (4) 50–100 mcg/kg ivi WPW:
   bolus Propanolol (7) 1–3 mg/kg 3–4
  Procainamide  infants 5–7mg/kg
   slow ivi
   children 7–15 mg/kg
   slow ivi
Junctional ectopic
tachycardia (JET) Amiodarone (6) 5 mg/kg loading  Amiodarone 2–5 mg/kg  1
Notes: 
(1) DC cardioversion: direct-current (DC) cardioversion is synchronised to QRS
(2) Congestive heart failure (CHF) 
(3) Vagal manoeuvres:
 Infants – apply ice to the face, gagging with tongue blade
 Children – above methods plus unilateral carotid massage and Valsalva manoeuvre doing a handstand 
(4) Adenosine is administered by rapid bolus at the usual starting dose of 100 mcg/kg/bolus with increases of 50 to 100 mcg/kg per 
bolus (maximum dose: 350 mcg/kg) if unsuccessful.
(5) Class 111a drugs such as d,l-sotalol and amiodarone are effective in 70% and 80% of cases in prevention of atrial flutter. The 
side-effects of amiodarone make it a less attractive option than d,l-sotalol.
(6) Postoperative JET is a life-threatening arrhythmia. In addition to hypothermia and atrial pacing, antiarrhythmia drugs are essential 
to overcome the first few critical days after surgery. Amiodarone is effective in both congenital and postoperative JET.
(7) Although propanolol and other beta-blockers are the drugs of choice in children with WPW; radio-frequency catheter ablation of 
the accessory pathway is the only curative treatment and therefore the preferred option.
CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 15, No. 2, March/April 2004                   69
very effective in terminating supraventricular tachycardias 
in our study. It is known to cause severe haemodynamic 
deterioration in infants and in patients with heart failure and 
is therefore contraindicated in this group.14 Due to its side 
effects, it is at present not being used.
Digoxin was the drug most commonly used for long-
term therapy. The majority of recurrences were within the 
first year of age: 11 of the 13 patients that relapsed were 
infants younger than one year.
Recommendations
In contrast with adult cardiology, there are no controlled 
studies on the treatment of children with supraventricular 
tachycardias. Therefore, in paediatric practice, the manage-
ment of supraventricular tachycardias is mainly based on 
clinical studies and individual experience.14 Care must be 
taken to choose medication regimens that are likely to be 
effective with the minimum risk of potentiating abnormal 
haemodynamics or conduction (Table III).
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